Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Top Cited Papers
- 10 June 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (23), 2187-2201
- https://doi.org/10.1056/nejmoa2101544
Abstract
The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. In an international, randomized, double-blind, placebo-controlled, phase 3 trial, we randomly assigned adult participants in a 1:1 ratio to receive a single dose of Ad26.COV2.S (5×1010 viral particles) or placebo. The primary end points were vaccine efficacy against moderate to severe–critical coronavirus disease 2019 (Covid-19) with an onset at least 14 days and at least 28 days after administration among participants in the per-protocol population who had tested negative for SARS-CoV-2. Safety was also assessed. The per-protocol population included 19,630 SARS-CoV-2–negative participants who received Ad26.COV2.S and 19,691 who received placebo. Ad26.COV2.S protected against moderate to severe–critical Covid-19 with onset at least 14 days after administration (116 cases in the vaccine group vs. 348 in the placebo group; efficacy, 66.9%; adjusted 95% confidence interval [CI], 59.0 to 73.4) and at least 28 days after administration (66 vs. 193 cases; efficacy, 66.1%; adjusted 95% CI, 55.0 to 74.8). Vaccine efficacy was higher against severe–critical Covid-19 (76.7% [adjusted 95% CI, 54.6 to 89.1] for onset at ≥14 days and 85.4% [adjusted 95% CI, 54.2 to 96.9] for onset at ≥28 days). Despite 86 of 91 cases (94.5%) in South Africa with sequenced virus having the 20H/501Y.V2 variant, vaccine efficacy was 52.0% and 64.0% against moderate to severe–critical Covid-19 with onset at least 14 days and at least 28 days after administration, respectively, and efficacy against severe–critical Covid-19 was 73.1% and 81.7%, respectively. Reactogenicity was higher with Ad26.COV2.S than with placebo but was generally mild to moderate and transient. The incidence of serious adverse events was balanced between the two groups. Three deaths occurred in the vaccine group (none were Covid-19–related), and 16 in the placebo group (5 were Covid-19–related). A single dose of Ad26.COV2.S protected against symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection and was effective against severe–critical disease, including hospitalization and death. Safety appeared to be similar to that in other phase 3 trials of Covid-19 vaccines. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.)Keywords
Funding Information
- HIV Vaccine Trials Network (UM1 AI68618)
- HIV Prevention Trials Network Leadership and Operations Center (UM1 AI68619)
- AIDS Clinical Trials Group Leadership and Operations Center (UM1 AI68636)
- Infectious Diseases Clinical Research Consortium Leadership Group (UM1 AI148684)
- Vaccine and Therapeutic Evaluation Units (UM1 AI148373, UM1 AI148452, UM1 AI148576, UM1 AI148685)
- National Institute of Allergy and Infectious Diseases
- HIV Vaccine Trials Network (UM1 AI68614)
- HVTN Statistics and Data Management Center (UM1 AI68635)
This publication has 36 references indexed in Scilit:
- Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With InfluenzaClinical Infectious Diseases, 2017
- Heterogeneity in disease risk induces falling vaccine protection with rising disease incidenceDynamical Systems, 2016
- Clinical trials: The mathematics of falling vaccine efficacy with rising disease incidenceVaccine, 2016
- Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 diseaseVaccine, 2015
- Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in ChildrenThe New England Journal of Medicine, 2013
- Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed InfluenzaClinical Infectious Diseases, 2013
- Statistics in Clinical Vaccine TrialsPublished by Springer Science and Business Media LLC ,2011
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007
- Multistage Designs for Vaccine Safety StudiesJournal of Biopharmaceutical Statistics, 2006
- Statistical approaches to establishing vaccine safetyStatistics in Medicine, 2002